Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Once-weekly high dose rate interstitial brachytherapy for carcinoma cervix is convenient, effective & well-tolerated

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Jyotirup Goswami

Citation

Annals of Oncology (2015) 26 (suppl_9): 80-84. 10.1093/annonc/mdv525

Authors

J. Goswami, S. Mallik, G. Kumar, B. Pal, S. Das

Author affiliations

  • Radiotherapy, Narayana Superspecialty Hospital, 711103 - Howrah/IN
More

Resources

Aim/Background

Interstitial brachytherapy (ISBT) in cervical cancer is used for post-operative gross residual disease and unoperated cases with poor anatomy/or bulky disease precluding intracavitary insertion. There is no standard dose fractionation schedule for ISBT. This study describes a logistically convenient schedule.

Methods

The study included 35 patients of advanced non-metastatic carcinoma cervix (squamous cell carcinoma & adenocarcinoma), 24 with bulky primary disease and 11 with vault recurrence/ residual, treated between June 2012 and December 2014. All patients underwent pelvic external beam radiotherapy (EBRT) using standard 4-field technique to a dose of 50Gy/25#/ 5 weeks; para-aortic nodes were treated if involved; concurrent chemotherapy was used wherever appropriate. Thereafter, the patients underwent 2 insertions of high dose rate (HDR) ISBT using the Syed-Neblett perineal template with titanium needles inserted percutaneously under spinal anaesthesia; ISBT was done once weekly as a daycare procedure; all patients underwent computerized tomography (CT) planning on the Brachyvision treatment planning software using volume optimization to achieve standard combined (ie EBRT+ ISBT) dose-volume constraints for 2cc of urinary bladder (EQD2 75Gy) & rectum (EQD2 70Gy) [EQD2= equivalent dose delivered at 2Gy per fraction]; prescribed dose was 9Gy /# to the high-risk clinical target volume.

Results

Thirty two patients (91.4%) achieved complete response and 3 achieved partial response. At a median follow-up of 20 months, 30 patients (85.7%) continue to be in remission. No patient had significant post-operative local pain/ bleeding; 4 patients had post-spinal headache persisting beyond 1 day; no patient had local skin/mucosal infection. There were 3 cases of grade 3 late rectal toxicity (8.57%) and none of grade 3 cystitis.

Conclusions

Once weekly HDR ISBT for carcinoma cervix is well-tolerated, convenient and effective. The difficulties of continuously retaining the perineal template over several days of continuous therapy, including pain, discomfort and local infection are easily avoided by this protocol.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings